The landscape of dementia prognosis has developed significantly with the appearance of advanced biomarkers, which include amyloid PET scans, tau imaging, and blood-primarily based assessments which can detect Alzheimer's pathology many years in advance of symptoms emerge. Even though these technological innovations represent impressive development